1. Home
  2. APRE vs CREV Comparison

APRE vs CREV Comparison

Compare APRE & CREV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APRE
  • CREV
  • Stock Information
  • Founded
  • APRE 2006
  • CREV 2007
  • Country
  • APRE United States
  • CREV Ireland
  • Employees
  • APRE N/A
  • CREV N/A
  • Industry
  • APRE Biotechnology: Biological Products (No Diagnostic Substances)
  • CREV
  • Sector
  • APRE Health Care
  • CREV
  • Exchange
  • APRE Nasdaq
  • CREV Nasdaq
  • Market Cap
  • APRE 9.7M
  • CREV 5.7M
  • IPO Year
  • APRE 2019
  • CREV N/A
  • Fundamental
  • Price
  • APRE $1.65
  • CREV $3.15
  • Analyst Decision
  • APRE Strong Buy
  • CREV
  • Analyst Count
  • APRE 2
  • CREV 0
  • Target Price
  • APRE $15.50
  • CREV N/A
  • AVG Volume (30 Days)
  • APRE 17.1K
  • CREV 43.1K
  • Earning Date
  • APRE 05-20-2025
  • CREV 01-01-0001
  • Dividend Yield
  • APRE N/A
  • CREV N/A
  • EPS Growth
  • APRE N/A
  • CREV N/A
  • EPS
  • APRE N/A
  • CREV N/A
  • Revenue
  • APRE $1,502,581.00
  • CREV $39,261,077.00
  • Revenue This Year
  • APRE N/A
  • CREV $40.76
  • Revenue Next Year
  • APRE N/A
  • CREV $86.18
  • P/E Ratio
  • APRE N/A
  • CREV N/A
  • Revenue Growth
  • APRE 157.63
  • CREV 41.52
  • 52 Week Low
  • APRE $1.41
  • CREV $2.00
  • 52 Week High
  • APRE $5.90
  • CREV $14.19
  • Technical
  • Relative Strength Index (RSI)
  • APRE 41.84
  • CREV 52.20
  • Support Level
  • APRE $1.67
  • CREV $2.78
  • Resistance Level
  • APRE $1.99
  • CREV $4.70
  • Average True Range (ATR)
  • APRE 0.14
  • CREV 0.48
  • MACD
  • APRE 0.04
  • CREV -0.01
  • Stochastic Oscillator
  • APRE 41.55
  • CREV 19.27

About APRE Aprea Therapeutics Inc. Common stock

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

About CREV Carbon Revolution Public Limited

Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.

Share on Social Networks: